Previous 10 | Next 10 |
2023-11-14 07:07:42 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Brainstorm Cell Therapeutics Inc. (BCLI) is expected to report $-0.14 for Q3 2023
2023-11-13 12:54:20 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , Nov. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseas...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Brainstorm C...
2023-10-24 08:17:04 ET BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) on Tuesday announced a strategic realignment to support accelerated development of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm ( BCLI ) holds the rights to clinical dev...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Tilray Brands Inc. (TLRY) rose 39.5% to $2.47 on volume of 149,005,559 shares Tesla Inc. (TSLA) fell 5.6% to $183.28 on volume of 125,934,900 shares PROSHARES TRUST (SQQQ) rose 5.7% to $11.95 on volume of 124,394,426 shares Jaguar H...
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegener...